GRAIL submitted the final module of its Premarket Approval (PMA) application on January 29, 2026, focusing on performance and safety data from 25,490 U.S. participants in the PATHFINDER 2 study and the first year of the NHS‑Galleri trial, the largest randomized controlled trial for a multi‑cancer early detection (MCED) test.
The submission includes a bridging analysis that compares the Galleri test version used in the PATHFINDER 2 and NHS‑Galleri studies to the updated PMA version, ensuring consistency between the clinical evidence and the commercial product that will be offered once FDA clearance is obtained.
FDA approval will allow GRAIL to transition from a direct‑pay model to a reimbursement‑based distribution framework, unlocking the projected $2.86 billion MCED market by 2030 and expanding access to the Galleri test across the United States.
GRAIL’s leadership highlighted the milestone, noting that the Galleri test addresses an unmet need in early cancer detection and that the PMA submission is a critical step toward broader availability. “Cancer is now the leading killer of adults over 50 years old in the U.S., and most deadly cancers are often discovered too late,” said Josh Ofman, president of GRAIL. “Adding Galleri to standard‑of‑care single cancer screening tests has the potential to dramatically improve the performance of the nation’s current screening program and expand opportunities for earlier treatment and improved outcomes.”
The company’s financial profile shows a $904 million cash runway, a pre‑profit status, and a Q3 2025 gross loss of $13.7 million, underscoring the need for FDA clearance to generate revenue and achieve profitability.
The announcement follows Illumina’s divestiture of GRAIL in 2024, placing the company in a competitive landscape that includes Freenome and Ezra. The NHS‑Galleri trial, which recruited over 140,000 participants, was temporarily paused due to performance concerns, highlighting ongoing scrutiny of MCED tests.
Investors remain cautious, awaiting the FDA’s decision, but view the PMA submission as a pivotal moment that could accelerate GRAIL’s commercial rollout and position it as a leader in the growing MCED market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.